- Trials with a EudraCT protocol (25)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
25 result(s) found for: Hematopoiesis.
Displaying page 1 of 2.
EudraCT Number: 2011-001118-32 | Sponsor Protocol Number: EP06-401 | Start Date*: 2011-05-25 | |||||||||||||||||||||
Sponsor Name:Sandoz GmbH | |||||||||||||||||||||||
Full Title: Twelve-month study on the immunogenicity, safety, and efficacy of Zarzio®/Filgrastim HEXAL® in patients with severe chronic neutropenia | |||||||||||||||||||||||
Medical condition: Severe chronic neutropenia (i.e. congenital neutropenia, cyclic neutropenia and chronic idiopathic neutropenia) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-001508-13 | Sponsor Protocol Number: COL-CHIPHF-P24 | Start Date*: 2021-08-06 |
Sponsor Name:Johann Wolfgang Goethe-Universität Frankfurt | ||
Full Title: Randomized, controlled, double-blind trial to investigate the effect of colchicin on the endothelial function in patients with CHIP mutations and chronic heart failure with reduced left ventricular... | ||
Medical condition: Ischemic heart failure with reduced ejection fraction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-003537-25 | Sponsor Protocol Number: 04032008 | Start Date*: 2008-08-28 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Can the steady-state hematopoiesis be improved post-ASCT by infusion of the autologous stem cell transplant directly in the bone marrow compartment. | ||
Medical condition: Study population - patient age 18-65 years - eligible for an ASCT for lymphoma or MM - at least ≥ 10 x 106 CD34+ cells/kg have been collected during the previous performed leucofereses procedure | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-002744-28 | Sponsor Protocol Number: IOM-510-2 | Start Date*: 2006-09-12 | |||||||||||
Sponsor Name:iOMEDICO | |||||||||||||
Full Title: Effektivitätsoptimierte und toxizitätsreduzierte Therapie des metastasierten Kolorektalkarzinoms in der First-line Therapie | |||||||||||||
Medical condition: metastastic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006367-26 | Sponsor Protocol Number: IGTRegs | Start Date*: 2023-01-03 |
Sponsor Name:Πανεπιστήμιο Πατρών | ||
Full Title: Phase I / II study of HLA-G + induced T-regulatory cells (iG-Tregs) in patients after allogeneic hematopoietic stem cell transplantation from HLA compatible sibling / donor. | ||
Medical condition: Adopt immunotherapy in adult patients undergoing hematopoietic stem cell (HSCT) transplantation from a fully compatible donor sibling for the prevention and treatment of GvHD. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003025-28 | Sponsor Protocol Number: TUD-RELAX1-070 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Technische Universität Dresden | |||||||||||||
Full Title: Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax | |||||||||||||
Medical condition: Patients 18-75 years with acute myeloid leukaemia (AML) at first or second relapse after intensive chemotherapy including allogeneic stem cell transplantation or primary refractory to standard indu... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002707-33 | Sponsor Protocol Number: GS-US-352-0101 | Start Date*: 2014-05-27 | |||||||||||
Sponsor Name:Sierra Oncology, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thromboc... | |||||||||||||
Medical condition: Primary Myleofibrosis (PMF) or post-Polycythemia vera or post-Essential Thrombocythemia Myelofibrosis (post-PV/ET MF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) BE (Completed) GB (Completed) AT (Completed) SE (Completed) ES (Completed) HU (Completed) NL (Completed) DK (Completed) BG (Completed) RO (Completed) PL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001541-26 | Sponsor Protocol Number: M16-106 | Start Date*: 2021-05-04 |
Sponsor Name:AbbVie Inc | ||
Full Title: A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma | ||
Medical condition: Acute Lymphoblastic Leukemia (ALL) Lymphoblastic Lymphoma | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001281-94 | Sponsor Protocol Number: A536-06 | Start Date*: 2015-03-11 | |||||||||||||||||||||
Sponsor Name:Acceleron Pharma, Inc. | |||||||||||||||||||||||
Full Title: An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 in Patients with β-Thalassemia Previously Enrolled in Study A536-04 | |||||||||||||||||||||||
Medical condition: β-Thalassemia Intermedia and β-Thalassemia major | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) GR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-002723-85 | Sponsor Protocol Number: EPO-ANE-3018 | Start Date*: 2009-02-11 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Epoetin Alfa Initiated at 40,000 IU Every Week or 80,000 IU Every Week Versus Placebo in Subjects With IPSS Low- or Inte... | |||||||||||||
Medical condition: subjects with International Prognostic Scoring Systems (IPSS) Low or Intermediate 1 risk myelodysplastic syndromes (MDS) who require any transfusion, compared with placebo, through Week 48. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001076-34 | Sponsor Protocol Number: ABNL-MARRO-001 | Start Date*: 2023-06-12 | ||||||||||||||||
Sponsor Name:Theradex (Europe) Ltd. | ||||||||||||||||||
Full Title: The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes | ||||||||||||||||||
Medical condition: Myelodysplastic syndrome/Myeloproliferative Neoplasm Overlap Syndromes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) AT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005007-13 | Sponsor Protocol Number: GS-US-352-1214 | Start Date*: 2014-10-21 | |||||||||||
Sponsor Name:Sierra Oncology, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized Study to Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibr... | |||||||||||||
Medical condition: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004553-17 | Sponsor Protocol Number: CC-4047-MMM-001 | Start Date*: 2007-04-24 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE 2, PROSPECTIVE, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, ACTIVE- CONTROL, PARALLEL-GROUP STUDY TO DETERMINE THE SAFETY OF AND TO SELECT A TREATMENT REGIMEN OF CC-4047 EITHER AS SINGLE-AGENT O... | |||||||||||||
Medical condition: Myelofibrosis with myeloid metaplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Completed) AT (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001947-28 | Sponsor Protocol Number: T2017-002 | Start Date*: 2019-06-11 | ||||||||||||||||
Sponsor Name:Therapeutic Advances in Childhood Leukemia Consortium (TACL) | ||||||||||||||||||
Full Title: A TACL Phase 1/2 Study of PO Ixazomib in Combination with Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | ||||||||||||||||||
Medical condition: Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LLy) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001718-80 | Sponsor Protocol Number: PRM-151G-101 | Start Date*: 2016-02-18 | |||||||||||||||||||||
Sponsor Name:Promedior, Inc | |||||||||||||||||||||||
Full Title: A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF) | |||||||||||||||||||||||
Medical condition: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) FR (Completed) DE (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-002682-19 | Sponsor Protocol Number: PHI113633 | Start Date*: 2013-12-20 | |||||||||||
Sponsor Name:GlaxoSmithKline, S.A. | |||||||||||||
Full Title: A Phase 2B, randomized, blinded, dose-ranging, active-controlled, parallel-group, multi-center study to evaluate the dose response relationship of GSK1278863 over the first 4 weeks of treatment and... | |||||||||||||
Medical condition: Anemia associated with chronic kidney disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SE (Completed) CZ (Completed) GB (Completed) DK (Completed) HU (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002681-39 | Sponsor Protocol Number: PHI113747 | Start Date*: 2013-12-20 | |||||||||||
Sponsor Name:GlaxoSmithKline, S.A. | |||||||||||||
Full Title: A 24-week, Phase 2B, randomized, active-controlled, parallel group, multi-center study to evaluate the safety and efficacy of GSK1278863 in subjects with anemia associated with chronic kidney disea... | |||||||||||||
Medical condition: Anemia associated with chronic kidney disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SE (Completed) GB (Completed) CZ (Completed) HU (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001048-40 | Sponsor Protocol Number: B1371013 | Start Date*: 2015-02-10 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, 10017 | |||||||||||||
Full Title: A phase 2, double-blind, randomized safety and efficacy study of Glasdegib (PF-04449913) versus placebo in patients with Myelofibrosis previously treated with ruxolitinib. | |||||||||||||
Medical condition: Myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) AT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001620-33 | Sponsor Protocol Number: WO29806 | Start Date*: 2015-11-12 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A Phase Ib/III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of vismodegib in combination with ruxolitinib versus placebo and ruxolitinib in patients with ... | |||||||||||||
Medical condition: Intermediate- or high-risk myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000981-40 | Sponsor Protocol Number: SWEAML12-A | Start Date*: 2013-01-23 | |||||||||||||||||||||
Sponsor Name:The Swedish AML Group | |||||||||||||||||||||||
Full Title: Azacitidine compared to conventional chemotherapy in consolidation of elderly patients (> 65 years) with AML in first complete remission | |||||||||||||||||||||||
Medical condition: | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.